{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:48:21Z","timestamp":1792792101585,"version":"4.5.0"},"reference-count":125,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chronic hepatitis B virus (HBV) infection is the largest global cause of hepatocellular carcinoma (HCC). Current HBV treatment options include pegylated interferon-alpha and nucleos(t)ide analogues (NAs), which have been shown to be effective in reducing HBV DNA levels to become undetectable. However, the literature has shown that some patients have persistent risk of developing HCC. The mechanism in which this occurs has not been fully elucidated. However, it has been discovered that HBV\u2019s covalently closed circular DNA (cccDNA) integrates into the critical HCC driver genes in hepatocytes upon initial infection; additionally, these are not targets of current NA therapies. Some studies suggest that HBV undergoes compartmentalization in peripheral blood mononuclear cells that serve as a sanctuary for replication during antiviral therapy. The aim of this review is to expand on how patients with HBV may develop HCC despite years of HBV viral suppression and carry worse prognosis than treatment-naive HBV patients who develop HCC. Furthermore, HCC recurrence after initial surgical or locoregional treatment in this setting may cause carcinogenic cells to behave more aggressively during treatment. Curative novel therapies which target the life cycle of HBV, modulate host immune response, and inhibit HBV RNA translation are being investigated.<\/jats:p>","DOI":"10.3390\/cancers16040777","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T06:59:26Z","timestamp":1707893966000},"page":"777","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-6605","authenticated-orcid":false,"given":"Nevin","family":"Varghese","sequence":"first","affiliation":[{"name":"Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amry","family":"Majeed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Nyalakonda","sequence":"additional","affiliation":[{"name":"Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Boortalary","sequence":"additional","affiliation":[{"name":"Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8298-5381","authenticated-orcid":false,"given":"Dina","family":"Halegoua-DeMarzio","sequence":"additional","affiliation":[{"name":"Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-8700","authenticated-orcid":false,"given":"Hie-Won","family":"Hann","sequence":"additional","affiliation":[{"name":"Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7150\/ijms.2.50","article-title":"Epidemiology and Prevention of Hepatitis B Virus Infection","volume":"2","author":"Hou","year":"2005","journal-title":"Int. J. Med. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/livers3020015","article-title":"Chronicles of HBV and the Road to HBV Cure","volume":"3","author":"Hann","year":"2023","journal-title":"Livers"},{"key":"ref_3","unstructured":"(2023, December 21). Hepatitis B. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0377-1237(07)80085-2","article-title":"Sleisenger and Fordtran\u2019s Gastrointestinal and Liver Disease: Pathophysiology, diagnosis, management","volume":"63","author":"Pithawa","year":"2007","journal-title":"Med. J. Armed Forces India"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","article-title":"Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B","volume":"118","author":"Kao","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis B virus genotypes: Global distribution and clinical importance","volume":"20","author":"Sunbul","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","article-title":"Immunobiology and pathogenesis of viral hepatitis","volume":"1","author":"Guidotti","year":"2006","journal-title":"Annu. Rev. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM200205303462202","article-title":"Chronic hepatitis B","volume":"346","author":"Lok","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3322\/canjclin.49.1.33","article-title":"Global cancer statistics","volume":"49","author":"Parkin","year":"1999","journal-title":"CA Cancer J. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2003-37590","article-title":"Natural history and prognosis of hepatitis B","volume":"23","author":"Fattovich","year":"2003","journal-title":"Semin. Liver Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis","volume":"132","author":"Rudolph","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"a021410","DOI":"10.1101\/cshperspect.a021410","article-title":"Hepatitis B virus epidemiology","volume":"5","author":"MacLachlan","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/infdis\/146.2.198","article-title":"Incidence of hepatitis B virus infections in preschool children in Taiwan","volume":"146","author":"Beasley","year":"1982","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/jama.1990.03440090052025","article-title":"The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies","volume":"263","author":"Alter","year":"1990","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/21505594.2022.2028483","article-title":"Pathogenicity and virulence of Hepatitis B virus","volume":"13","author":"Chuang","year":"2022","journal-title":"Virulence"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection\u2013Natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Khanam, A., Chua, J.V., and Kottilil, S. (2021). Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115497"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Noverati, N., Bashir-Hamidu, R., Halegoua-DeMarzio, D., and Hann, H.W. (2022). Hepatitis B Virus-Associated Hepatocellular Carcinoma and Chronic Stress. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073917"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1572-0241.1998.00354.x","article-title":"Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers","volume":"93","author":"Liaw","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.patbio.2009.11.001","article-title":"Pathogenesis of hepatitis B virus infection","volume":"58","author":"Chisari","year":"2010","journal-title":"Pathol. Biol."},{"key":"ref_22","unstructured":"Tripathi, N., and Mousa, O.Y. (2023). StatPearls, Statpearls Publishing."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10395","DOI":"10.3748\/wjg.v20.i30.10395","article-title":"Natural history of chronic hepatitis B: Phases in a complex relationship","volume":"20","author":"Croagh","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_24","first-page":"398","article-title":"Characterization of T-cell tolerance to hepatitis B virus (HBV) antigen in transgenic mice","volume":"75","author":"Takashima","year":"1992","journal-title":"Immunology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.3748\/wjg.15.3099","article-title":"Molecular characteristics and stages of chronic hepatitis B virus infection","volume":"15","author":"Shi","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3350\/cmh.2017.0068","article-title":"Management of chronic hepatitis B patients in immunetolerant phase: What latest guidelines recommend","volume":"24","author":"Wong","year":"2018","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.21724","article-title":"Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase","volume":"46","author":"Hui","year":"2007","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/hep.22898","article-title":"The natural history of chronic hepatitis B virus infection","volume":"49","author":"McMahon","year":"2009","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cgh.2010.02.023","article-title":"Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B","volume":"8","author":"Jeng","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.23348","article-title":"Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B","volume":"51","author":"Chen","year":"2010","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0016-5085(86)90395-1","article-title":"Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe","volume":"90","author":"Bonino","year":"1986","journal-title":"Gastroenterology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1136\/gut.25.11.1283","article-title":"Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection","volume":"25","author":"Lok","year":"1984","journal-title":"Gut"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/cid\/ciy598","article-title":"Mortality Among Patients With Chronic Hepatitis B Infection: The Chronic Hepatitis Cohort Study (CHeCS)","volume":"68","author":"Bixler","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/286533a0","article-title":"Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma","volume":"286","author":"Brechot","year":"1980","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2008.12.003","article-title":"Hepatitis B virus induced hepatocellular carcinoma","volume":"286","author":"Chemin","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.ejca.2010.03.034","article-title":"Hepatitis B virus-related hepatocarcinogenesis: Molecular oncogenic potential of clear or occult infections","volume":"46","author":"Cassini","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jhep.2009.10.033","article-title":"Mechanisms of HBV-related hepatocarcinogenesis","volume":"52","author":"Neuveut","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"HEP35","DOI":"10.2217\/hep-2020-0028","article-title":"Hepatitis B-related hepatocellular carcinoma and stress: Untangling the host immune response from clinical outcomes","volume":"8","author":"Block","year":"2020","journal-title":"Hepat. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4234061","DOI":"10.1155\/2016\/4234061","article-title":"Insights into the Role and Interdependence of Oxidative Stress and Inflammation in Liver Diseases","volume":"2016","author":"Li","year":"2016","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Peneau, C., Zucman-Rossi, J., and Nault, J.C. (2021). Genomics of Viral Hepatitis-Associated Liver Tumors. J. Clin. Med., 10.","DOI":"10.3390\/jcm10091827"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/apt.12207","article-title":"Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma","volume":"37","author":"Wong","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","article-title":"Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma","volume":"100","author":"Yang","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/JCM.40.1.22-25.2002","article-title":"Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C","volume":"40","author":"Kao","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review","volume":"53","author":"Papatheodoridis","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2008.03.073","article-title":"Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B\/C infection: A follow-up study in Taiwan","volume":"135","author":"Chen","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.cgh.2017.12.009","article-title":"Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen","volume":"16","author":"Tse","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/hepr.12427","article-title":"Risk of hepatocellular carcinoma in cirrhotic hepatitis B virus patients during nucleoside\/nucleotide analog therapy","volume":"45","author":"Orito","year":"2015","journal-title":"Hepatol. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.cgh.2018.08.019","article-title":"Spontaneous Seroclearance of Hepatitis B Surface Antigen and Risk of Hepatocellular Carcinoma","volume":"17","author":"Song","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1158\/1055-9965.EPI-19-0303","article-title":"The Influence of Metabolic Syndrome on the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection in Mainland China","volume":"28","author":"Tan","year":"2019","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Motta, B.M., Masarone, M., Torre, P., and Persico, M. (2023). From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention. Cancers, 15.","DOI":"10.20944\/preprints202310.1078.v1"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/apt.16335","article-title":"Systematic review with meta-analysis: Bariatric surgery reduces the incidence of hepatocellular carcinoma","volume":"53","author":"Ramai","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/infdis\/jiq096","article-title":"Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B","volume":"203","author":"Yeung","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/gut.2007.119859","article-title":"Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B\/C, specific mutations of enhancer II\/core promoter\/precore regions and HBV DNA levels","volume":"57","author":"Yuen","year":"2008","journal-title":"Gut"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2012.03.004","article-title":"Why men are at higher risk for hepatocellular carcinoma?","volume":"57","author":"Keng","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8184","DOI":"10.1038\/s41598-021-87679-w","article-title":"Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide\/nucleoside analogues","volume":"11","author":"Jang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-3-030-03502-0_9","article-title":"HIV-HBV and HIV-HCV Coinfection and Liver Cancer Development","volume":"177","author":"Hu","year":"2019","journal-title":"Cancer Treat. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2995","DOI":"10.1097\/MD.0000000000002995","article-title":"Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection","volume":"95","author":"Yang","year":"2016","journal-title":"Medicine"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"(2010). Clinical Practice Guidelines for Hepatocellular Carcinoma-The Japan Society of Hepatology 2009 update. Hepatol. Res., 40, 2\u2013144.","DOI":"10.1111\/j.1872-034X.2010.00650.x"},{"key":"ref_61","unstructured":"European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1053\/j.gastro.2019.02.049","article-title":"Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction","volume":"157","author":"Kanwal","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/1573394716666200129121051","article-title":"Vagaries of the Host Response in the Development of Hepatitis B-related Hepatocellular Carcinoma: A Case Series","volume":"16","author":"Block","year":"2020","journal-title":"Curr. Cancer Ther. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000529153","article-title":"The Role of Host in the Spectrum of Outcomes in Family Clusters of Hepatitis Infection: From Asymptomatic to Hepatocellular Carcinoma","volume":"17","author":"Noverati","year":"2023","journal-title":"Case Rep. Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.3748\/wjg.v24.i30.3347","article-title":"Host genetic factors affecting hepatitis B infection outcomes: Insights from genome-wide association studies","volume":"24","author":"Akcay","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1053\/j.gastro.2015.02.004","article-title":"Association between Psychological Distress and Liver Disease Mortality: A Meta-analysis of Individual Study Participants","volume":"148","author":"Russ","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e01235","DOI":"10.1002\/brb3.1235","article-title":"A literature review for the mechanisms of stress-induced liver injury","volume":"9","author":"Joung","year":"2019","journal-title":"Brain Behav."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"He, Y., Gao, H., Li, X., and Zhao, Y. (2014). Psychological stress exerts effects on pathogenesis of hepatitis B via type-1\/type-2 cytokines shift toward type-2 cytokine response. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105530"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.3748\/wjg.v27.i22.2994","article-title":"Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment","volume":"27","author":"Granito","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.3748\/wjg.v17.i38.4258","article-title":"Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma","volume":"17","author":"Han","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.29537","article-title":"Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/apt.12344","article-title":"Meta-analysis: The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B","volume":"38","author":"Singal","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"100847","DOI":"10.1016\/j.jhepr.2023.100847","article-title":"Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"5","author":"Lim","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/jvh.12283","article-title":"Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort","volume":"22","author":"Papatheodoridis","year":"2015","journal-title":"J. Viral Hepat."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"939","DOI":"10.5009\/gnl15527","article-title":"Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma","volume":"10","author":"Kim","year":"2016","journal-title":"Gut Liver"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/jac\/dkt147","article-title":"Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants","volume":"68","author":"Yang","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/S0168-8278(13)60654-6","article-title":"652 virological response to entecavir is associated with low probability of developing hepatocellular carcinoma in chronic Hepatitis B patients with cirrhosis","volume":"58","author":"Kim","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"ref_82","first-page":"74","article-title":"Persistent risk for hepatocellular carcinoma after more than a decade of successful hepatitis B virus suppression","volume":"63","author":"Dargan","year":"2017","journal-title":"Minerva Gastroenterol. Dietol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/gut.2010.221846","article-title":"Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: Results of the nationwide HEPNET. Greece cohort study","volume":"60","author":"Papatheodoridis","year":"2011","journal-title":"Gut"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4254\/wjh.v11.i1.65","article-title":"Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure","volume":"11","author":"Shinn","year":"2019","journal-title":"World J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.3748\/wjg.v19.i47.8822","article-title":"Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy","volume":"19","author":"Vlachogiannakos","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Yoo, J., Hann, H.W., Coben, R., Conn, M., and DiMarino, A.J. (2018). Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure. Diseases, 6.","DOI":"10.3390\/diseases6020027"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhep.2004.10.026","article-title":"Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance","volume":"42","author":"Ahn","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/apt.13621","article-title":"Nested case-control study: Hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance","volume":"43","author":"Gounder","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/hep.31230","article-title":"Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer","volume":"72","author":"Li","year":"2020","journal-title":"Hepatology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3350\/cmh.2022.0342","article-title":"Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection","volume":"29","author":"Lin","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2893.2010.01321.x","article-title":"Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy","volume":"18","author":"Coffin","year":"2011","journal-title":"J. Viral Hepat."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2020.05.042","article-title":"Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance","volume":"73","author":"Mak","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cgh.2019.06.029","article-title":"Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis","volume":"18","author":"Wong","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.1840170106","article-title":"Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: A study of a low-endemic area","volume":"17","author":"Paterlini","year":"1993","journal-title":"Hepatology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2003.10.048","article-title":"Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection","volume":"126","author":"Pollicino","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/hep.510290329","article-title":"Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis","volume":"29","author":"Michalak","year":"1999","journal-title":"Hepatology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B","volume":"67","author":"Kim","year":"2018","journal-title":"Gut"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/JLB.2A1118-421R","article-title":"STAT3 directly regulates NKp46 transcription in NK cells of HBeAg-negative CHB patients","volume":"106","author":"Zheng","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jhep.2019.06.032","article-title":"Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection","volume":"71","author":"Delphin","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21037\/amj.2018.02.01","article-title":"Immune tolerant HBV and HCC: Time to revise our tolerance levels for therapy?","volume":"3","author":"Zhou","year":"2018","journal-title":"AME Med. J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1053\/j.gastro.2020.02.027","article-title":"Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?","volume":"158","author":"Howell","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","article-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA","volume":"146","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/hep.23934","article-title":"Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options","volume":"52","author":"Jonas","year":"2010","journal-title":"Hepatology"},{"key":"ref_106","first-page":"105","article-title":"Are We Close to Achieving a HBV Cure? Risk for Hepatocellular Carcinoma Persists Despite Long-term HBV Suppression: An Update on Our Experience","volume":"1","author":"Boortalary","year":"2020","journal-title":"Arch. Gastroenterol. Res."},{"key":"ref_107","unstructured":"Sergi, C.M. (2021). Liver Cancer [Internet], Exon Publications. Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK569795\/."},{"key":"ref_108","first-page":"86","article-title":"Survival Disparity Between Antiviral-Treated and Antiviral-Na\u00efve Patients Who Develop Their First HBV-Associated Hepatocellular Carcinoma","volume":"2","author":"Garrido","year":"2021","journal-title":"Arch. Gastroenterol. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.29245\/2578-3009\/2023\/1.1242","article-title":"Poor Prognosis in HBV-associated Hepatocellular Carcinoma After Successful Viral Suppression: A Case Series Highlighting a Need for a Cure","volume":"7","author":"Chowdhury","year":"2023","journal-title":"J. Immunol. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1245\/s10434-009-0694-z","article-title":"A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection","volume":"17","author":"Li","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Lin, S.Y., Zhang, A., Lian, J., Wang, J., Chang, T.T., Lin, Y.J., Song, W., and Su, Y.H. (2021). Recurrent HBV Integration Targets as Potential Drivers in Hepatocellular Carcinoma. Cells, 10.","DOI":"10.3390\/cells10061294"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.3748\/wjg.v24.i36.4152","article-title":"Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and\/or prognostic markers?","volume":"24","author":"Marisi","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Liu, L., Lv, Z., Wang, M., Zhang, D., Liu, D., and Zhu, F. (2023). HBV Enhances Sorafenib Resistance in Hepatocellular Carcinoma by Reducing Ferroptosis via SRSF2-Mediated Abnormal PCLAF Splicing. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043263"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Liu, L.J., Lv, Z., Xue, X., Xing, Z.Y., and Zhu, F. (2022). Canonical WNT Signaling Activated by WNT7B Contributes to L-HBs-Mediated Sorafenib Resistance in Hepatocellular Carcinoma by Inhibiting Mitophagy. Cancers, 14.","DOI":"10.3390\/cancers14235781"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13027-021-00359-2","article-title":"Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression","volume":"16","author":"Zhang","year":"2021","journal-title":"Infect. Agent. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2021.08.029","article-title":"Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B","volume":"76","author":"Gao","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"104800","DOI":"10.1016\/j.phrs.2020.104800","article-title":"CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma","volume":"157","author":"Gao","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2014.07.004","article-title":"Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib","volume":"352","author":"Mao","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s13577-023-00945-z","article-title":"MiR-3677-3p promotes development and sorafenib resistance of hepatitis B-related hepatocellular carcinoma by inhibiting FOXM1 ubiquitination","volume":"36","author":"He","year":"2023","journal-title":"Hum. Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.tranon.2018.02.015","article-title":"Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus","volume":"11","author":"Fridkin","year":"2018","journal-title":"Transl. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.coviro.2016.06.003","article-title":"HBV cure: Why, how, when?","volume":"18","author":"Levrero","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.gastro.2022.10.008","article-title":"Current Best Practice in Hepatitis B Management and Understanding Long-term Prospects for Cure","volume":"164","author":"Yardeni","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.cgh.2023.02.032","article-title":"New Perspectives on Development of Curative Strategies for Chronic Hepatitis B","volume":"21","author":"Feld","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/777\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:59:37Z","timestamp":1760104777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":125,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["cancers16040777"],"URL":"https:\/\/doi.org\/10.3390\/cancers16040777","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]}}}